An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China
Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis. We performed...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2023-11, Vol.17 (11), p.e0011785-e0011785 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0011785 |
|---|---|
| container_issue | 11 |
| container_start_page | e0011785 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 17 |
| creator | Gong, Dandan Lin, Weiyin Zhang, Huihua Ou, Xu Li, Liya Guo, Pengle He, Yaozu Liu, Cong Cai, Weiping Tang, Xiaoping Li, Linghua |
| description | Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.
We performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People's Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977-0.987, P |
| doi_str_mv | 10.1371/journal.pntd.0011785 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3069183548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A775219126</galeid><doaj_id>oai_doaj_org_article_209d6d6a085245289fe2f8ef291e28de</doaj_id><sourcerecordid>A775219126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-b7ea24b1b699137141ce80d1489fefd446b671130df8bd5cb7d9ec338df0ef543</originalsourceid><addsrcrecordid>eNptksFu1DAQhiMEoqXwBggiISEO7GI7ceIcVytoVyriAlwtxx5nvfLawXZW2hfgdXgIXoykm1YtqnywNfr-md8zk2WvMVriosafdn4ITthl75JaIoRxzeiT7Bw3BV2QuqBP773Pshcx7hCiDWX4eXZWsJEnuDrPfq9cDgdhB5GMd7nX-dce97lwyXTg8igDgDOuy7UPeRJWBL8_Sh9NzI3LrzY_F8ZpkAnUjSZACv5ggrB52kIQ_XHhxN8_B8h73w_2VGQUXg7Cdcq77mO-3honXmbPtLARXs33Rfbjy-fv66vF9bfLzXp1vZAUs7RoaxCkbHFbNc3UhBJLYEjhkjUatCrLqq1qjAukNGsVlW2tGpBFwZRGoGlZXGRvT3l76yOfWxh5gaoGs4KWbCQ2J0J5seN9MHsRjtwLw28CPnRchGSkBU5QoypVCcQoKSmZPBDNQJMGA2EKxlwf5mrB_xogJr43UYK1woEfIh8lZU0wIZOxd_-hj5ubqU6M9cfO-xSEnJLyVV1TghtMqpFaPkKNR8HeSO9AmzH-QPD-nmALwqZt9HaYphUfguUJlMHHGEDfNQgjPg3k1jWftpLPWznK3syfG9o9qDvR7RoW_wDLZN9Z</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3069183548</pqid></control><display><type>article</type><title>An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><creator>Gong, Dandan ; Lin, Weiyin ; Zhang, Huihua ; Ou, Xu ; Li, Liya ; Guo, Pengle ; He, Yaozu ; Liu, Cong ; Cai, Weiping ; Tang, Xiaoping ; Li, Linghua</creator><creatorcontrib>Gong, Dandan ; Lin, Weiyin ; Zhang, Huihua ; Ou, Xu ; Li, Liya ; Guo, Pengle ; He, Yaozu ; Liu, Cong ; Cai, Weiping ; Tang, Xiaoping ; Li, Linghua</creatorcontrib><description>Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.
We performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People's Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977-0.987, P<0.01). The optimal cut-off point of the CD4+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.
Mp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0011785</identifier><identifier>PMID: 38011216</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Antibodies ; Antigens ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Antiviral agents ; Assaying ; CD4 antigen ; CD4 Lymphocyte Count ; Complications and side effects ; Cross-Sectional Studies ; Culture ; Culture techniques ; Cytomegalovirus ; Diagnosis ; Drug therapy ; ELISA ; Enrollments ; Enzyme-linked immunosorbent assay ; Enzymes ; Health aspects ; Highly active antiretroviral therapy ; HIV ; HIV (Viruses) ; HIV infection ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV patients ; HIV testing ; Hospitals ; Human immunodeficiency virus ; Humans ; Infection ; Infections ; Medical colleges ; Medical research ; Medicine, Experimental ; Mortality ; Mycoses - diagnosis ; Pathogens ; Patient outcomes ; Patients ; Population ; Regression analysis ; Viral antibodies</subject><ispartof>PLoS neglected tropical diseases, 2023-11, Vol.17 (11), p.e0011785-e0011785</ispartof><rights>Copyright: © 2023 Gong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Gong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c518t-b7ea24b1b699137141ce80d1489fefd446b671130df8bd5cb7d9ec338df0ef543</cites><orcidid>0000-0001-5711-8681</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pntd.0011785&type=printable$$EPDF$$P50$$Gplos$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.plos.org/plosone/article?id=10.1371/journal.pntd.0011785$$EHTML$$P50$$Gplos$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,2915,23845,27901,27902,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38011216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gong, Dandan</creatorcontrib><creatorcontrib>Lin, Weiyin</creatorcontrib><creatorcontrib>Zhang, Huihua</creatorcontrib><creatorcontrib>Ou, Xu</creatorcontrib><creatorcontrib>Li, Liya</creatorcontrib><creatorcontrib>Guo, Pengle</creatorcontrib><creatorcontrib>He, Yaozu</creatorcontrib><creatorcontrib>Liu, Cong</creatorcontrib><creatorcontrib>Cai, Weiping</creatorcontrib><creatorcontrib>Tang, Xiaoping</creatorcontrib><creatorcontrib>Li, Linghua</creatorcontrib><title>An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.
We performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People's Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977-0.987, P<0.01). The optimal cut-off point of the CD4+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.
Mp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiviral agents</subject><subject>Assaying</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Complications and side effects</subject><subject>Cross-Sectional Studies</subject><subject>Culture</subject><subject>Culture techniques</subject><subject>Cytomegalovirus</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>ELISA</subject><subject>Enrollments</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Health aspects</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV infection</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV patients</subject><subject>HIV testing</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Medical colleges</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Mycoses - diagnosis</subject><subject>Pathogens</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Population</subject><subject>Regression analysis</subject><subject>Viral antibodies</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptksFu1DAQhiMEoqXwBggiISEO7GI7ceIcVytoVyriAlwtxx5nvfLawXZW2hfgdXgIXoykm1YtqnywNfr-md8zk2WvMVriosafdn4ITthl75JaIoRxzeiT7Bw3BV2QuqBP773Pshcx7hCiDWX4eXZWsJEnuDrPfq9cDgdhB5GMd7nX-dce97lwyXTg8igDgDOuy7UPeRJWBL8_Sh9NzI3LrzY_F8ZpkAnUjSZACv5ggrB52kIQ_XHhxN8_B8h73w_2VGQUXg7Cdcq77mO-3honXmbPtLARXs33Rfbjy-fv66vF9bfLzXp1vZAUs7RoaxCkbHFbNc3UhBJLYEjhkjUatCrLqq1qjAukNGsVlW2tGpBFwZRGoGlZXGRvT3l76yOfWxh5gaoGs4KWbCQ2J0J5seN9MHsRjtwLw28CPnRchGSkBU5QoypVCcQoKSmZPBDNQJMGA2EKxlwf5mrB_xogJr43UYK1woEfIh8lZU0wIZOxd_-hj5ubqU6M9cfO-xSEnJLyVV1TghtMqpFaPkKNR8HeSO9AmzH-QPD-nmALwqZt9HaYphUfguUJlMHHGEDfNQgjPg3k1jWftpLPWznK3syfG9o9qDvR7RoW_wDLZN9Z</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Gong, Dandan</creator><creator>Lin, Weiyin</creator><creator>Zhang, Huihua</creator><creator>Ou, Xu</creator><creator>Li, Liya</creator><creator>Guo, Pengle</creator><creator>He, Yaozu</creator><creator>Liu, Cong</creator><creator>Cai, Weiping</creator><creator>Tang, Xiaoping</creator><creator>Li, Linghua</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5711-8681</orcidid></search><sort><creationdate>20231101</creationdate><title>An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China</title><author>Gong, Dandan ; Lin, Weiyin ; Zhang, Huihua ; Ou, Xu ; Li, Liya ; Guo, Pengle ; He, Yaozu ; Liu, Cong ; Cai, Weiping ; Tang, Xiaoping ; Li, Linghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-b7ea24b1b699137141ce80d1489fefd446b671130df8bd5cb7d9ec338df0ef543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiviral agents</topic><topic>Assaying</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Complications and side effects</topic><topic>Cross-Sectional Studies</topic><topic>Culture</topic><topic>Culture techniques</topic><topic>Cytomegalovirus</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>ELISA</topic><topic>Enrollments</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Health aspects</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV infection</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV patients</topic><topic>HIV testing</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Medical colleges</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Mycoses - diagnosis</topic><topic>Pathogens</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Population</topic><topic>Regression analysis</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gong, Dandan</creatorcontrib><creatorcontrib>Lin, Weiyin</creatorcontrib><creatorcontrib>Zhang, Huihua</creatorcontrib><creatorcontrib>Ou, Xu</creatorcontrib><creatorcontrib>Li, Liya</creatorcontrib><creatorcontrib>Guo, Pengle</creatorcontrib><creatorcontrib>He, Yaozu</creatorcontrib><creatorcontrib>Liu, Cong</creatorcontrib><creatorcontrib>Cai, Weiping</creatorcontrib><creatorcontrib>Tang, Xiaoping</creatorcontrib><creatorcontrib>Li, Linghua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gong, Dandan</au><au>Lin, Weiyin</au><au>Zhang, Huihua</au><au>Ou, Xu</au><au>Li, Liya</au><au>Guo, Pengle</au><au>He, Yaozu</au><au>Liu, Cong</au><au>Cai, Weiping</au><au>Tang, Xiaoping</au><au>Li, Linghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>17</volume><issue>11</issue><spage>e0011785</spage><epage>e0011785</epage><pages>e0011785-e0011785</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.
We performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People's Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977-0.987, P<0.01). The optimal cut-off point of the CD4+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.
Mp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>38011216</pmid><doi>10.1371/journal.pntd.0011785</doi><orcidid>https://orcid.org/0000-0001-5711-8681</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2023-11, Vol.17 (11), p.e0011785-e0011785 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_3069183548 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Public Library of Science (PLoS) |
| subjects | Acquired immune deficiency syndrome Adult AIDS Antibodies Antigens Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiviral agents Assaying CD4 antigen CD4 Lymphocyte Count Complications and side effects Cross-Sectional Studies Culture Culture techniques Cytomegalovirus Diagnosis Drug therapy ELISA Enrollments Enzyme-linked immunosorbent assay Enzymes Health aspects Highly active antiretroviral therapy HIV HIV (Viruses) HIV infection HIV Infections - complications HIV Infections - drug therapy HIV patients HIV testing Hospitals Human immunodeficiency virus Humans Infection Infections Medical colleges Medical research Medicine, Experimental Mortality Mycoses - diagnosis Pathogens Patient outcomes Patients Population Regression analysis Viral antibodies |
| title | An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A27%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20evaluation%20of%20Mp1p%20antigen%20screening%20for%20talaromycosis%20in%20HIV-infected%20antiretroviral%20therapy-na%C3%AFve%20population%20in%20Guangdong,%20China&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Gong,%20Dandan&rft.date=2023-11-01&rft.volume=17&rft.issue=11&rft.spage=e0011785&rft.epage=e0011785&rft.pages=e0011785-e0011785&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0011785&rft_dat=%3Cgale_plos_%3EA775219126%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3069183548&rft_id=info:pmid/38011216&rft_galeid=A775219126&rft_doaj_id=oai_doaj_org_article_209d6d6a085245289fe2f8ef291e28de&rfr_iscdi=true |